These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 11359800)

  • 1. The role of adoptively transferred CD8 T cells and host cells in the control of the growth of the EG7 thymoma: factors that determine the relative effectiveness and homing properties of Tc1 and Tc2 effectors.
    Helmich BK; Dutton RW
    J Immunol; 2001 Jun; 166(11):6500-8. PubMed ID: 11359800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous type 1 antitumor responses.
    Dobrzanski MJ; Reome JB; Hollenbaugh JA; Dutton RW
    J Immunol; 2004 Feb; 172(3):1380-90. PubMed ID: 14734713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic effects of tumor-reactive type 1 and type 2 CD8+ T cell subpopulations in established pulmonary metastases.
    Dobrzanski MJ; Reome JB; Dutton RW
    J Immunol; 1999 Jun; 162(11):6671-80. PubMed ID: 10352285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of effector cell-derived IL-4, IL-5, and perforin in early and late stages of type 2 CD8 effector cell-mediated tumor rejection.
    Dobrzanski MJ; Reome JB; Dutton RW
    J Immunol; 2001 Jul; 167(1):424-34. PubMed ID: 11418679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity.
    Kemp RA; Ronchese F
    J Immunol; 2001 Dec; 167(11):6497-502. PubMed ID: 11714817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Type 1 and type 2 CD8+ effector T cell subpopulations promote long-term tumor immunity and protection to progressively growing tumor.
    Dobrzanski MJ; Reome JB; Dutton RW
    J Immunol; 2000 Jan; 164(2):916-25. PubMed ID: 10623840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effector cell-derived lymphotoxin alpha and Fas ligand, but not perforin, promote Tc1 and Tc2 effector cell-mediated tumor therapy in established pulmonary metastases.
    Dobrzanski MJ; Reome JB; Hollenbaugh JA; Hylind JC; Dutton RW
    Cancer Res; 2004 Jan; 64(1):406-14. PubMed ID: 14729652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relative diabetogenic properties of islet-specific Tc1 and Tc2 cells in immunocompetent hosts.
    Vizler C; Bercovici N; Heurtier A; Pardigon N; Goude K; Bailly K; Combadière C; Liblau RS
    J Immunol; 2000 Dec; 165(11):6314-21. PubMed ID: 11086068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perforin-mediated effector function within the central nervous system requires IFN-gamma-mediated MHC up-regulation.
    Bergmann CC; Parra B; Hinton DR; Chandran R; Morrison M; Stohlman SA
    J Immunol; 2003 Mar; 170(6):3204-13. PubMed ID: 12626579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Type 1 CD8+ T cells are superior to type 2 CD8+ T cells in tumor immunotherapy due to their efficient cytotoxicity, prolonged survival and type 1 immune modulation.
    Ye Z; Tang C; Xu S; Zhang B; Zhang X; Moyana T; Yang J; Xiang J
    Cell Mol Immunol; 2007 Aug; 4(4):277-85. PubMed ID: 17764618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The rate of the CD8-dependent initial reduction in tumor volume is not limited by contact-dependent perforin, Fas ligand, or TNF-mediated cytolysis.
    Hollenbaugh JA; Reome J; Dobrzanski M; Dutton RW
    J Immunol; 2004 Aug; 173(3):1738-43. PubMed ID: 15265903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disparate cytotoxic activity of nickel-specific CD8+ and CD4+ T cell subsets against keratinocytes.
    Traidl C; Sebastiani S; Albanesi C; Merk HF; Puddu P; Girolomoni G; Cavani A
    J Immunol; 2000 Sep; 165(6):3058-64. PubMed ID: 10975816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Signal 3 availability limits the CD8 T cell response to a solid tumor.
    Curtsinger JM; Gerner MY; Lins DC; Mescher MF
    J Immunol; 2007 Jun; 178(11):6752-60. PubMed ID: 17513722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD8+ T cell subsets TC1 and TC2 cause different histopathologic forms of murine cardiac allograft rejection.
    Delfs MW; Furukawa Y; Mitchell RN; Lichtman AH
    Transplantation; 2001 Mar; 71(5):606-10. PubMed ID: 11292288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential requirement of perforin and IFN-gamma in CD8 T cell-mediated immune responses against B16.F10 melanoma cells expressing a viral antigen.
    Prévost-Blondel A; Neuenhahn M; Rawiel M; Pircher H
    Eur J Immunol; 2000 Sep; 30(9):2507-15. PubMed ID: 11009083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo persistence of CD8 polarized T cell subsets producing type 1 or type 2 cytokines.
    Cerwenka A; Carter LL; Reome JB; Swain SL; Dutton RW
    J Immunol; 1998 Jul; 161(1):97-105. PubMed ID: 9647212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent immunotherapy against well-established thymoma using adoptively transferred transgene IL-6-engineered dendritic cell-stimulated CD8+ T-cells with prolonged survival and enhanced cytotoxicity.
    Kalyanasundaram Bhanumathy K; Zhang B; Xie Y; Xu A; Tan X; Xiang J
    J Gene Med; 2015; 17(8-9):153-60. PubMed ID: 26212685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human Tc1 and Tc2/Tc0 CD8 T-cell clones display distinct cell surface and functional phenotypes.
    Vukmanovic-Stejic M; Vyas B; Gorak-Stolinska P; Noble A; Kemeny DM
    Blood; 2000 Jan; 95(1):231-40. PubMed ID: 10607707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma.
    Fowler DH; Gress RE
    Leuk Lymphoma; 2000 Jul; 38(3-4):221-34. PubMed ID: 10830730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential expression and costimulatory effect of 4-1BB (CD137) and CD28 molecules on cytokine-induced murine CD8(+) Tc1 and Tc2 cells.
    Vinay DS; Kwon BS
    Cell Immunol; 1999 Feb; 192(1):63-71. PubMed ID: 10066348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.